Supplementary data.docx

Supporting Figure 1. Partial DNA sequence of p53R213X gene   harbored in the pLenti-CMV-p53R213X plasmid. A TGA codon was introduced at the   position of 628-630.

Supporting Figure 2. Partial cDNA sequence of the p53R213X   gene reversely-transcripted from the H1299p53R213X cells treated   with 200 mM G418 for 72 h. A TGA codon was   located at the position of 608-610.

Supporting Figure 3. Partial cDNA sequence of the p53R213X   gene reversely-transcripted from the H1299p53R213X cells treated   with 200 mM Dox (a random   control) for 72 h. A TGA codon was located at the position of 608-610.

Supporting Figure 4. Partial cDNA sequence of the p53R213X   gene reversely-transcripted from the H1299p53R213X cells after the   cells were cultured for 72 h (a negative control). A TGA codon was   located at the position of 609-611.

Supporting Figure 5. MTT assay of the viabilities of the H1299 (a) and H1299p53R213X cells (b) treated with different doses of G418 in combination with 200 mM MMS for 24 h, and n = 3   independent experiments and the data are represented as mean values ± SD.

Supporting Figure 6. Inducible expression of the FL-p53 and   TR-p53 protein. Expression levels of FL-p53 and TR-p53 were estimated with western   blotting after the H1299p53R213X cells (right), in comparison with   the H1299 cells (left). β-Actin was used as the loading control, and n=3   independent experiments. (a) Cells were   treated with different dose of G418 for 48 h. (b) Cells were treated with different dose of G418 in   combination with 200 mM MMS for 24 h.